
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (8) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (9) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (4)
- Complementary medicines (22) Apply Complementary medicines filter
- Cosmetics (2) Apply Cosmetics filter
- Disinfectants/Sterilants (4) Apply Disinfectants/Sterilants filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (23) Apply Labelling/Packaging filter
- Legislation (20) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Manufacturing (11) Apply Manufacturing filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medical devices/IVDs (48) Apply Medical devices/IVDs filter
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (1) Apply Medicines filter
- OTC medicines (31) Apply OTC medicines filter
- Prescription medicines (25) Apply Prescription medicines filter
- Safety of medicines & medical devices (2) Apply Safety of medicines & medical devices filter
- Scheduling (37) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (6) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (6)
Fees and charges proposal 2020-21
Closed on 28 February 2020
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Fees and charges proposal 2019-20
Closed on 8 February 2019
Revision of TGO 75 Standard for haematopoietic progenitor cells derived from cord blood
Closed on 7 July 2017
Options for the future regulation of 'low risk' products
Closed on 12 May 2017
Regulation of autologous stem cell therapies
Closed on 3 March 2015
Review of the low value turnover exemption scheme
Closed on 23 May 2014
Evaluating the feasibility of a new-to-market risk communication scheme for therapeutic goods
Closed on 13 June 2013